Key Drivers
- Strong Liquidity
- Ongoing Cash Burn
- Equity Dilution
AIAI Summary
TSHA's extended cash runway into 2H 2028 shifts the thesis from near-term financing risk to a high-conviction binary on whether TSHA-102's pivotal Rett data and 1H 2027 FDA feedback support a viable BLA; investors should treat the stock as catalyst-driven upside with substantial downside if efficacy, safety, or regulatory alignment disappoints.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Cash Burn
- •Equity Dilution
TSHA has a strong liquidity cushion, but persistent losses, cash burn, dilution, and an extremely high sales multiple make it a high-risk, execution-dependent investment.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Weak rebound
- •Critical support
TSHA remains bearish after an 18% decline, with $5.00–$5.02 support critical and a move above $5.60 needed to improve momentum.
Roughly 18% decline over the last month
Sentiment & News
Key News Insights:
- •Institutional accumulation
- •Rett syndrome progress
- •Execution milestones
TSHA gains institutional backing and Rett syndrome momentum, but remains a high-risk, catalyst-driven play dependent on pivotal clinical and manufacturing execution.
Positive early data and extended cash runway support upside potential, though clinical and operational risks remain significant
Similar Companies in Healthcare
Other companies in the same sector with AI ratings